Outcomes of penicillin allergy de-labelling
A total of 56 patients were successfully de-labelled in the pilot study but a key challenge will be preventing the erroneous reappearance of the penicillin allergy label, according… read more.
A total of 56 patients were successfully de-labelled in the pilot study but a key challenge will be preventing the erroneous reappearance of the penicillin allergy label, according… read more.
Incorrect penicillin allergy labels can result in patients receiving less effective or more toxic antimicrobial agents but a recent publication has shown that a pharmacy-led multidisciplinary team can… read more.
Madagascar is one of the poorest countries in the world and access to health care is limited for many people. Childhood vaccinations are a crucial component of preventative… read more.
Scientists at Washington University in St. Louis have developed a breath test that quickly identifies those who are infected with the virus that causes COVID-19. The device requires… read more.
More than half of patients with auto-immune conditions experience mental health conditions such as depression or anxiety, yet the majority are rarely or never asked in clinic about… read more.
-Sandoz, a global leader in generic pharmaceuticals and biosimilars, announced that the citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United… read more.
Deborah Evans is Superintendent Pharmacist and Clinic Director at Remedi Health, where she runs a weight management service, including the provision of semaglutide. In this series of short… read more.
Vaccines against COVID-19, administered in the EU in the autumn of 2023, will be updated to target XBB forms of the SARS-CoV-2 virus. These strains are a subgroup… read more.
Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the… read more.
Deborah Evans is superintendent pharmacist and clinic director at Remedi Health, an independent pharmacy and healthcare clinic in Winchester. Remedi Health runs a weight management service and has… read more.
Takeda announced that the FDA has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years… read more.
A global phase 3 clinical trial that included Ann & Robert H. Lurie Children’s Hospital of Chicago found that a year-long immunotherapy through a skin patch safely desensitized… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.